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Glycogen storage disease is a group of inborn errors of metabolism, with type Ia being
the most common form of the disorder. Glycogen storage disease type Ia (GSDIa) is a
multisystemic condition in which individuals have various complications secondary to an
inability to properly break down glycogen and to perform gluconeogenesis. Complex
management is then necessary for patients and includes dietary modification, frequent
cornstarch usage, and evaluation for additional complications such as hepatic adenoma s,
hypertriglyceridemia, and kidney disease . Previous studies have found lower scores in
quality of life and body image in GSDIa patients; however, the specific factors
influencing this relationship remain unknown. In this study, 24 adult participants (n=24)
with glycogen storage disease type Ia completed a survey including measures of healthrelated quality of life, body image, and metabolic control. Results found that quality of
life was significantly lower than the general population on both the physical and mental
component scores (t=-3.11, p=0.005; t=-2.21, p=0.03). Additionally, body image was
significantly lower on all subscales: Weight (t= -5.88, p<0.001), Appearance (t=-5.67,
p<0.001), and Attribution (t=-2.38, p=0.02). In general, significance was not reached
when examining roles that certain metabolic and demographic factors play in healthrelated quality of life and body image. Therefore, the relationship between these factors
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is most likely complex. Overall, the current study confirms previous fin dings of lower
health-related quality of life and body image in this population and provides preliminary
evidence on potential factors influencing this phenomenon.
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INTRODUCTION
The glycogen storage diseases are a group of disorders characterized by abnormalities in
various enzymes that are involved in glycogen synthesis and/or degradation. Each subtype of
glycogen storage disease have varying enzymatic deficiencies, in turn leading to varying phenotypic
expression. Glycogen storage disease type Ia, also known as von Gierke disease, is due to deficiency
of glucose-6-phosphotase (G6Pase) activity (Hendriksz & Gissen, 2015). G6Pase is expressed in the
liver and is responsible for catalyzing final reactions of glycogenolysis and gluconeogenesis. The lack
of activity of the G6Pase protein leads to a decrease in glucose output from the liver during fasting.
Furthermore, the build-up of glucose-6-phosphate leads to increased G6P in glycolysis and increased
lactate production. The gene that encodes G6Pase is called G6PC and is located on chromosome
17q21 (Ozen, 2007; Wolfsdorf & Weinstein, 2003). GSDIa is inherited in an autosomal recessive
manner; therefore, individuals with GSDIa have bi-allelic pathogenic variants in G6PC.
Metabolic derangements of GSDIa include severe fasting hypoglycemia, lactic acidosis,
hypertriglyceridemia and hyperuricemia. The clinical features of this condition are multisystemic and
may include seizures, lethargy, and failure to thrive. In addition to low glucose levels, there is also
buildup of glycogen in these patients, leading to hepatomegaly. Patients with GSDIa may exhibit
short stature and characteristic facial features including a round “doll”-like face with full cheeks
(Kishnani et al., 2014). Complications arise in the context of poor metabolic control and manifest as
hepatic adenomas, renal disease, severe hypoglycemia potentially leading to brain damage,
osteoporosis/osteopenia, and anemia (Kishnani et al., 2014). According to ACMG guidelines on
management of GSD type I, care for these patients should occur in the context of a multidisciplinary
team with expertise in glycogen storage disease (Kishnani et al., 2014). Various specialists should be
involved, including nephrology, hepatology, hematology, genetics, and cardiology, in addition to
metabolic disease specialists. Additionally, the specific diet required for these individuals is a lactose,
galactose, sucrose, and fructose free diet. This is further managed through the use of frequent
cornstarch dose given every 3 to 4 hours, during the day and at night, often times necessitating use of
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a G-tube. Understandably this form of management then can have a significant impact on the daily
routines of individuals with GSDIa.
Researchers have suggested that further information on the relationship between metabolic
control, body image, and quality of life would be useful to elucidate potential influencing factors of
quality of life of patients with GSD (Flanagan et al., 2015). This research could provide insight for
direction of adherence to diet and mental health care discussions for these patients. Because metabolic
control as a factor influencing quality of life and body image in these patients has not been evaluated
in depth before, the current study aims to further examine this question by eliciting information on the
relationship between metabolic control, body image, and quality of life (QoL) in adult patients with
glycogen storage disease type Ia. The authors hypothesize that individuals with better self-assessed
and objective measures of metabolic control will have better quality of life and body esteem.

METHODS
Data was collected via a survey, using the system Qualtrics (Qualtric, Provo, UT) and
consisting of four parts: demographics, metabolic control, quality of life, and body image.
To evaluate for level of metabolic control, patients completed questions regarding amount of
complications they report per week, what they are using for treatment of complications and
hypoglycemia, and what their own perceived level of metabolic control was. Level of control in the
study is defined as the degree to which individuals follow management and dietary guidelines.
Participants were asked if they consider themselves to be under good metabolic control and to rate
their level of metabolic control on a scale of 1 to 10, with 10 representing highest level of control.
Participants were also asked about their frequency and dosage of cornstarch used and whether they
take Glycosade™. The metabolic control section consisted of 21 questions in total.
Short-Form 36 Version 2 (SF-36v2) Health Survey from OPTUM QualityMetric, Inc was
used to measure Health-Related Quality of Life (HRQoL) in adult patients with GSDIa (Ware &
Sherbourne, 1992). SF-36v2 is a 36 item validated and reliable measure of health-related quality of
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life in the adult population. Subscales include physical functioning, role physical, bodily pain, general
health perception vitality, social functioning, role emotional, and mental health. The mental
component score (MCS) and physical component score (PCS), which are summary measures for
mental and physical aspects of health-related quality of life, were used in analysis in the current
study. Scores on the measure were standardized and converted to a 0-100 scale for analysis (Maruish;
Ware & Sherbourne, 1992).
Body image was measured using the Body Esteem Scale (Mendelson, Mendelson, & White,
2001). The Body Esteem Scale is a validated measure analyzing level of satisfaction or dissatisfaction
with one’s body and is comprised of three subscales. These subscales include Attribution, Weight,
and Appearance. The Attribution subscale relates to the individuals perceptions on how others view
their body. The Weight subscale represents their own perceptions about their weight and their
satisfaction with their body. The Appearance subscale deals with how people perceive their own
physical appearance and facial features. The scale consists of 30 items, answers for which take the
format of a 5-point scale (0-4) (Mendelson et al., 2001). Of note, this measure was translated into
Spanish by one of the researchers and the measure has not been previously validated in this language
before.
A link to the survey was posted to the Association of Glycogen Storage Disease US website
(https://agsdus.org), Glucolatino listserv, and glycogen storage disease patient Facebook groups, and
a recruitment flyer was sent via mail to patients currently enrolled in the GSD program at McGovern
Medical School at UTHealth. The survey was available in both English and Spanish. Inclusion
criteria for this study included any patient with a diagnosis of GSDIa who was over the age of 18,
who clicked on the survey link and who consented to participate. Exclusion criteria included
individuals who do not fall into the aforementioned categories or who do not have a diagnosis of
GSDIa. Finally, the study was only available to individuals who speak either English or Spanish.
Originally, parents of children with GSD type Ia and adolescents aged 13-17 with GSDIa were
included in the study, however these groups were removed due to low sample size and response rate.
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Overall, specific response rate was unable to be calculated due to a lack of information about how
many individuals who fit the criteria saw the link to the survey, but did not choose to complete it.
Statistical analysis was completed using the software Stata (v13.1, College Station, TX,
USA). SF-36 and the Body Esteem Scale were scored using the recommended methods and
compared to population norms (Maruish; Mendelson et al., 2001). Body image and QoL were
compared to the US general population using one sample t-tests. Rank sum was used to evaluate subgroups due to the small sample size. Significance was assumed at a Type I error rate of 5%.

RESULTS
Twenty-four adult patients with a diagnosis of GSDIa completed the survey. All surveys were
fully completed except in one individual who did not complete the Body Esteem Scale (n = 23). The
sample consisted of 5 male (21%) and 19 female participants and a majority identified as being
Caucasian (88%, n=21) and from the United States (58%, n=14). Of individuals who reported being
from the United States, the most commonly represented state was Texas (21%, n=3), followed by
New York (14%, n=2). The age of participants ranged from 20-57 years old (median = 31). Three of
the 24 participants (13%) completed the survey in Spanish.
The median age of diagnosis for the sample was 0.5 years, with the range being from birth to
20 years old. One could argue about verity of diagnosis for the individuals diagnosed at 20 years and
19 years respectively due to the severity of the condition, however removal of these individuals from
analysis did not significantly impact statistical results and therefore they were included. Average
height of the sample was 158 cm with the average weight being 68.9 kg. One individual did not
provide their weight and therefore sample size for weight and BMI are 23. Average BMI was 27.3
kg/m2 (SD = 6) with 11 (48%) having a ‘healthy’ BMI (18.5-24.9 kg/m2) and 12 (52%) having a BMI
classified as being overweight (>25 kg/m2). No individuals had a BMI falling in the underweight
category.
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Table 1. Demographic characteristics
Count
Frequency (%)
Gender
Male
5
20.8%
Female
19
79.2%
Current Age
Age of Diagnosis (years)
Height (cm)
Weight (kg) n = 23
BMI n=23
Race
Caucasian
21
87.5%
Asian
2
8.3%
Other
1
4.2%
Ethnicity
Non-Hispanic
20
83.3%
Hispanic
4
16.7%
Country
United States
14
58.3%
Mexico
2
8.3%
Canada
2
8.3%
Spain
1
4.2%
Germany
1
4.2%
Portugal
1
4.2%
Argentina
1
4.2%
Denmark
1
4.2%
Israel
1
4.2%
State
Texas
3
21.4%
New York
2
14.3%
Michigan
1
7.1%
South Carolina
1
7.1%
Colorado
1
7.1%
New Jersey
1
7.1%
Illinois
1
7.1%
Wisconsin
1
7.1%
Illinois
1
7.1%
Virginia
1
7.1%
Alabama
1
7.1%

Mean (SD)

Median (IQR)

32.1 (9.1)
2.7 (5.4)
158.4 (7.7)
68.9 (16.9)
27.3 (6.0)

31 (25-38)
0.5 (0.3-1.8)
157.7 (153.2-164.1)
70.3 (56.0-78.0)
25.8 (22.2-30.6)
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A majority of individuals reported checking their glucose at home (75%, n=18). Of those
individuals, 56% (n=10) of them reported checking their glucose when they think that they are low,
and 33% (n=6) checking multiple times a day. 11% (n=2) reported that they check their glucose once
a day. Two individuals (8%) reported receiving tube feedings, with both individuals using g-tubes.
Twenty individuals reported taking cornstarch (83%), with 18 providing some level of information on
their cornstarch schedule. Of these 18, 10 individuals (55%) noted that they had sleep interrupted due
to having to wake up to take cornstarch. Other reported medications used by the sample including
25% (n=6) who take Glycosade™ and 50% (n=12) who take allopurinol.
A majority of individuals reported having 1 to 5 low blood sugars a week (67%, n=16), with
21% (n=5) being unsure how many they had. One individual each reported having no, 6 to 10,
and >10 episodes of hypoglycemia a week. In terms of complications related to GSD 54% (n=13) of
the sample reported having liver masses/hepatic adenomas, 25% (n=6) having osteoporosis, 46%
(n=11) having kidney problems/kidney stones, 67% (n=16) having hypoglycemia every week at least
once a week, and 92% (n=22) have high cholesterol or high triglycerides. Using those five
complications listed, the mean number of complications for the sample was 2.8 with a standard
deviation of 1.3.
Given scale of one to ten with ten being the highest control and one being the lowest, the
mean self-perceived level of control for the sample was 5.9 with a standard deviation of 1.6. When
looking at frequency of responses, no individuals reported scores of 1, 2, 9, and 10 (Figure 1). The
most common reported score was 4 (26%). Additionally, 54% (n=13) consider themselves to be under
good metabolic control (Table 2).
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Table 2. Clinical characteristics and measures of control
Count Frequency (%)
Do you check your glucose at home?
18
75%
Do you receive tube feedings?
No
22
91.7%
Yes
2
8.3%
How often do you check your glucose?
Multiple times a day
6
33.3%
Once a day
2
11.1%
When I think I am low
10
55.6%
How many LBS's do you have per week?
None
1
4.2%
1 to 5
16
66.7%
6 to 10
1
4.2%
>10
1
4.2%
Not sure
5
20.9%
Complications reported
Liver masses/hepatic adenomas
13
54.2%
Osteoporosis
6
25.0%
Kidney problems/Kidney stones
11
45.8%
Low blood sugars every week
16
66.7%
High cholesterol or triglycerides
22
91.7%
Number of complications (see above for list of
complications)
On a scale of 1 to 10 rate your level of
metabolic control (10 being best control)
Do you consider yourself to be under
good metabolic control?
No
11
45.8%
Yes
13
54.2%

Mean (SD)

Median (IQR)

2.8 (1.3)

3 (2.0-3.5)

5.9 (1.6)

6.0 (4.0-7.0)
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7
6

Frequency

5
4
3
2
1
0
1

2

3

4

5

6

7

8

9

10

Scale of Control
Figure 1. Scale of Control
Frequency of response regarding self-perceived level of control on a scale of 1 to 10, with 1
representing poorest control and 10 representing best control. Most individuals fell in the
middle values, with no responses falling in levels 1, 2, 9, or 10.

Adult patients with glycogen storage disease type Ia were found to have lower health-related
quality of life scores than the general population using the physical component score (PCS) (t=-3.11,
p=0.005) and the mental component score (MCS) (t=-2.21, p=0.03) (Table 3). There was no
statistically significant difference in quality of life found between males and females in both PCS
(p=0.594) and MCS (p=0.414) (Table 4).
In reference to body image, adult patients with GSDIa were found to have statistically
significantly lower scores than the general population in all three subscales of body esteem: Weight
(p<0.001), Appearance (p<0.001), and Attribution (p=0.02). (Table 3). When stratifying based on
gender, females were found to be significantly lower than gender norms in Weight (p=0.002) and
Appearance (p=0.005), but not Attribution (p=0.09). Similarly when comparing males in the sample
to gender norms, they scored significantly lower in the Appearance subscale (p=0.04), but not the
Weight (p=0.07) or Attribution subscale (p=0.12).
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Table 3. QoL and body esteem compared to population controls
Scales
Count
Mean (SD)
Median (IQR)
SF-36
n=24
Physical Component Score
(PCS)
46.1 (8.6)
47.1 (41.9-51.9)
Mental Component Score
(MCS)
42.8 (11.3)
43.7 (35.3-51.1)
Body Esteem Scale
(BES)
n=23
Weight
1.4 (0.9)
1.5 (0.6-1.8)
Appearance
1.4 (1.0)
1.3 (0.6-2.2)
Attribution
1.8 (0.9)
1.8 (1.0-2.3)

t-score

p-value

-3.11

0.005

-2.21

0.03

-5.88
-5.67
-2.38

<0.001
<0.001
0.02

When examining factors related to metabolic control and their influence on outcome
measures including the MCS and PCS subscales of QoL, the Weight, Appearance, and Attribution
subscales of the BES, and self-reported control on a scale of one to ten, a majority of factors were
found to have no effect (Table 4). Men and women did not report significantly different scores in
quality of life, body esteem, of scale of control. Checking glucose at home, taking cornstarch, taking
Glycosade™, waking up at night, and receiving tube feedings were not significantly associated with
scores on QoL, BES, or perceived metabolic control (Table 4). Individuals who considered
themselves to be under good metabolic control reported significantly higher responses on scale of
control (p<0.001). Taking allopurinol was significantly associated with scale of control, such that
individuals who take allopurinol reported higher levels of self-perceived control (p=0.0155).
Individuals taking allopurinol and/or Glycosade™ had higher control than those who took neither
(p=0.009). However, there was no difference seen between individuals taking one or the other and
those taking both (p=0.1255). Taking both allopurinol and Glycosade™ was also significantly
associated with BMI, such that individuals who take both have on average higher BMI’s that
individuals who take one or the other (p=0.009) and those who take neither (p=0.008). There was no
difference in BMI seen between individuals who took neither allopurinol nor Glycosade™ and those
who took one or the other (p=0.437). This relationship was also seen in reference to the Weight
subscale of the BES. Individuals who took both Glycosade™ and allopurinol reported poorer scores
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of the Weight subscale than individuals that took one or the other (p=0.014) and those who took
neither (p=0.0497).
Table 4. Potential factors influencing outcome measures
Gender
Male (n=5)
MCS
PCS
Weight
Appearance
Attribution
Scale of control

Mean (SD)
40.5 (9.0)
48.9 (12.1)
1.68 (1.26)
1.36 (0.94)
1.8 (1.11)
7.0 (1.0)

Median (IQR)
42.7 (38.8-44.3)
50.9 (42.1-55.5)
1.5 (0.89-2.25)
1.3 (1.2-1.7)
1.6 (1-2)
7.0 (6.0-8.0)

Female (n=19)
Mean (SD)
43.4 (11.9)
45.4 (7.7)
1.28 (0.86)
1.38 (0.99)
1.74 (0.90)
5.6 (1.65)

p-value

Median (IQR)
44.3 (34.7-52.5)
47.0 (41.9-50.7)
1.5 (0.36-1.75)
0.90 (0.40-2.30)
1.80 (1.00-2.40)
5.5 (4.0-7.0)

0.594
0.4136
0.5673
1.00
0.7752
0.0866

Do you consider yourself to be under good metabolic control?
No (n=11)
MCS
PCS
Weight
Appearance
Attribution
Scale of control

Mean (SD)
39.3 (12.4)
45.9 (9.4)
1 (0.7)
1.1 (0.9)
1.8 (0.6)
4.5 (1.0)

Median (IQR)
37.8 (26.1 - 51.9)
47 (36.3 - 50.7)
1.5 (0.1 - 1.5)
0.8 (0.4 - 2.1)
2 (1.6 - 2.2)
4 (4 - 6)

Yes (n=13)
Mean (SD)
45.8 (9.8)
46.3 (8.2)
1.7 (1)
1.6 (1)
1.7 (1.1)
7.1 (1)

p-value

Median (IQR)
44.3 (38.8 - 50.4)
48.1 (42.1 - 52.8)
1.6 (0.9 - 2.3)
1.7 (0.9 - 2.3)
1.6 (1 - 2.6)
7 (6.5 - 8)

0.284
0.728
0.103
0.271
0.705
<0.001

Do you check your glucose at home?
No (n=6)
MCS
PCS
Weight
Appearance
Attribution
Scale of control

Mean (SD)
38.1 (14.5)
45 (8.5)
1.25 (1.13)
0.9 (1.08)
1.67 (0.98)
5.3 (1.97)

Median (IQR)
39.3 (24.8-50.3)
44.6 (41.9-50.9)
1.13 (0.25-1.75)
0.60 (0.30-0.90)
1.70 (1.00-2.60)
5.0 (4.0-7.0

Yes (n=18)
Mean (SD)
44.4 (10.0)
46.5 (8.8)
1.4 (0.90)
1.53 (0.90)
1.78 (0.98)
6.1 (1.5)

p-value

Median (IQR)
44.3 (37.7-51.9)
47.6 (42.1-52.9)
1.50 (0.88-1.75)
1.50 (0.80-2.30)
1.80 (1.20-2.20)
6.0 (5.0-7.0)

0.3173
0.6407
0.6388
0.1169
0.9466
0.3711
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Do you take cornstarch?
No (n=4)

Yes (n=20)

p-value

MCS
PCS
Weight

Mean (SD)
37.6 (15.2)
38.8 (11.8)
1.72 (1.23)

Median (IQR)
37.7 (28.3-47.0)
33.5(31.8-45.7)
1.81(0.94-2.50)

Mean (SD)
43.9 (10.5)
47.6 (7.3)
1.29 (0.89)

Median (IQR)
44.3( 35.3-51.1)
47.7 (42.5-51.9)
1.50 (0.56-1.69)

0.4386
0.1213
0.2753

Appearance
Attribution
Scale of control

1.13 (1.27)
1.55 (1.15)
5.0 (2.6)

0.62 (0.32-1.95)
1.70 (0.60-2.50)
4.0 (3.0-8.0)

1.42 (0.92)
1.79 (0.90)
6.0 (1.5)

1.30 (0.75-2.20)
1.80 (1.10-2.20)
6.0 (4.5-7.0)

0.4614
0.8458
0.3755

Do you take allopurinol?
No (n=12)
MCS
PCS
Weight
Appearance
Attribution
Scale of control

Mean (SD)
41.5 (10.7)
44 (8.9)
1.48 (0.54)
1.42 (0.86)
1.78 (0.89)
5.0 (1.5)

Median (IQR)
42.3 (34.8-50.3)
43.6 (35.7-51.7)
1.50 (1.44-1.75)
1.30 (0.75-2.20)
1.80 (1.10-2.30)
4.0 ( 4.0-7.0)

Yes (n=12)
Mean (SD)
44.1 (12.2)
48.3 (8.0)
1.25 (1.23)
1.33 (1.09)
1.72 (0.99)
6.67 (1.4)

p-value

Median (IQR)
42.7 (36.7-54.0)
47.7 (43.2-53.1)
0.81 (0.31-2.13)
1.25 (0.40-2.20)
1.80 (0.90-2.40)
3.0 (2.0-4.5)

0.6033
0.2481
0.2826
0.8397
0.8847
0.0155

Do you take Glycosade™?
No (n=18)
MCS
PCS
Weight
Appearance
Attribution
Scale of control

Mean (SD)
42.2 (11.1)
46 (9.3)
1.44 (0.96)
1.41 (0.98)
1.81 (0.98)
5.8 (1.78)

Median (IQR)
42.9 (35.9-51.9)
46.1 (41.9-52.8)
1.50 (0.88-1.8)
1.25 (0.70-2.30)
1.90 (1.00-2.40
6.0 (4.0-8.0)

Yes (n=6)
Mean (SD)
44.6 (12.7)
46.5 (6.7)
1.15 (0.89)
1.28 (1.01)
1.57 (0.79)
6.0 (1.26)

p-value

Median (IQR)
48.6 (34.7-50.4)
47.7 (41.9-50.2)
1.25 (0.38-1.75)
1.30 (0.40-1.80)
1.60 (1.00-2.20)
6.5 (5.0-7.0)

0.6892
0.9734
0.7885
0.8413
0.6155
0.858

DISCUSSION
This study aimed to provide more information about quality of life and body image in
individuals with glycogen storage disease type Ia and also to examine the role that various factors of
metabolic control play in these measures. Results found that quality of life and body image are both
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impaired in adult patients with GSDIa and have provided preliminary data on factors that could
influence this relationship.
Previous studies have examined quality of life in patients with glycogen storage disease type
I. An Italian multisite study performed by Sechi et al. in 2014 found that patients with GSD type I
reported lower scores on general health perception and social functions and better scores in bodily
pain and mental health in comparison to previously published normal control values for the measure
(Sechi et al., 2014). However, unlike the current study, they did not find any statistically significant
differences in comparison to US norms for the physical and mental composite scores. Reasons for this
difference include that perhaps Italian patients with GSDI have better quality of life than individuals
in the US, or it could reflect an overall higher baseline quality of life in Italian individuals in the
general population unrelated to having GSD. Overall, our data supports the general conclusions from
Sechi et al. that adult patients with GSD report lower quality of life than the general population and
also increases the generalizability of these findings, given that the original study included only Italian
individuals.
Flanagan et al. examined eating disorder symptoms, eating attitudes, and body esteem using
validated questionnaires and interviews in a previous study on body image in patients with all
subtypes of GSD. They reported body esteem scores in children and adults lower than the population
norm (Flanagan et al., 2015). When looking at specific subscales however, only Attribution was
statistically significant, while in the current study participants reported significantly lower scores on
all subscales. Therefore, our data similarly confirms their results that adult patients with GSD have
lower levels of body esteem than the general population.
To the best of our knowledge this was the first study to examine why individuals with GSDIa
have low quality of life and body image. Measures relating to demographics and metabolic control
were evaluated to determine the nature of their relationship to outcome measures. For demographic
factors, only gender was found to play a role. Females, in general, reported lower self-perceived
control than males; however, this result was not statistically significant. Previous studies of the
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general population have found that women self-report lower physical and mental health status than
men (Bertakis et al, 2000). Our data seems to support this trend in the GSD population as well.
In reference to factors of metabolic control, individuals who use g-tubes had generally lower
scores on the Attribution subscale of the BES. External devices have been shown to impact body
image due to visibility of the device (Bolton, Lobben, & Stern, 2010). Therefore, these individuals
could feel as though others are judging them for the g-tube, thereby lowering their body esteem. Of
note, this trend was not significant, and only 2 individuals reported using g-tubes and therefore this
data should be interpreted with caution. Additionally, taking Glycosade™ was not found to impact
QoL and body image, which supports results of previous studies that have found that Glycosade™
does not impact QoL (Correia et al, 2008; Rousseau-Nepton et al, 2018).
Complications reported were also found to be a significant factor in QoL and body image.
They were found at similar levels to what has previously been reported in individuals with glycogen
storage disease as adults (Talente et al., 1994). As expected, almost every listed complication was
significantly associated with overall number of complications reported. However, this statistical
significance was not reached for high cholesterol/triglycerides. This association may not have been
seen due to the large number of individuals with high cholesterol in the general population.
Interestingly, high cholesterol has been previously linked with obesity and high BMI in the general
population, however this relationship was not found in our sample (Mokdad et al., 2003). In terms of
the role these complications may play in body esteem and quality of life, having low blood sugars at
least once a week every week and having kidney stones/kidney problems were both found to be
significant in their role in body esteem. Particularly, individuals who reported having either
complication were found to have statistically significantly poorer scores on the Attribution subscale
of the BES, suggesting these complications may play a role in QoL and body image.
Overall, while significant associations were found that influence perceived level of control,
QoL, and body image in patients with GSDIa, there were no individual factors seen to strongly drive
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the low QoL and body image in this population. Therefore, the relationship between factors of
metabolic control and QoL and body image is most likely complex.
Results of the study also highlight the difference in objective and subjective measures of
metabolic control. For example, individuals taking allopurinol, an objective sign of poor control,
reported better self-perceived control than those who did not. Taking medication may be influencing
perceived control or symptom relief, with a consequent sense of well-being. Studies on other chronic
conditions have seen medical adherence related to higher perceived control, as well (Broadbent,
Donkin, & Stroh, 2011). From this, one could recommend increased focus on medical adherence due
to the relationship between taking allopurinol and perception of control. The importance of subjective
experience in various avenues is well-characterized. Subjective perceptions have been shown to have
more of an effect on predicting disordered eating than objective measures of weight (Wilson, Tripp,
& Boland, 2005). Additionally, subjective experience has been shown to be an important factor in
QoL in the general population (Diener & Suh, 1997). It is important to recognize that while
individuals may have objectively poorer metabolic control, their subjective control may be high,
allowing them to have higher QoL and body image than what would be expected based solely on
objective measures.
Current guidelines for management of GSD type I include care by a team aware of the
psychosocial considerations of the condition and discuss referral to a social worker or similar
specialist if issues become apparent (Kishnani et al, 2014; Rake et al, 2002). This study supports
results from previous studies finding that patients with GSDIa have lower quality of life and body
image than the general population. It is then important for guidelines to address this subject in future
management guidelines in more detail. There also likely exists a complex relationship in the
development of low quality of life and body image in these patients. Therefore, targeted intervention
to address concerns regarding body image and QoL would not be helpful and should instead be
offered for all patients. Additionally, results of the study highlight the importance of objective versus
subjective control and that objective control should not be the sole factor in determining individuals at
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risk for issues related to QoL and body image. Future research should be performed evaluating
accuracy in perception of metabolic control and the weight of objective versus subjective control in
outcomes for these individuals. Additional research should also examine these findings in the context
of a larger sample and for other subtypes of GSD, as complications of each differ (Chen & Weinstein,
2016). Overall, while psychosocial concerns may become apparent in childhood and adolescence in
these patients, it is necessary to bring awareness to the fact that adult patients also report difficulty
with body image and quality of life and therefore management in this context should be present
throughout the lifetime.
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